MacroGenics competitors

Ryan Spencer is a Board Member at Dynavax Technologies and Chief Executive Officer at Dynavax Technologies and is based in Berkeley, California. He has worked as Senior Director Commercial Operations at Dynavax Technologies; Senior Product Director, HEPLISAV-B at Dynavax Technologies; and Vice President, Corporate Strategy & Commercial Operations at Dynavax Technologies. Ryan attended Universidade Federal de Santa Catarina between 1995 and 1999.

J Scott Wolchko are a President/CEO/COO at FATE THERAPEUTICS INC and Board Member at FATE THERAPEUTICS INC. They have worked as Chief Financial Officer at Bocada and VP:Operations/CFO at FATE THERAPEUTICS INC. J studied at University of Virginia and Alpha Omega Alpha Medical Honor Society.

Michael Castagna is a Board Member at MANNKIND CORP and Chief Executive Officer at MANNKIND CORP and is based in Westlake Village, California. He has worked as Vice President & Head, Biopharmaceuticals North America at Sandoz; Director, Endocrinology Marketing at Healthcare Business of Merck; and VP/Global Head:Commercial at Amgen. Michael attended Massachusetts College of Pharmacy and Health Sciences between 2012 and 2014, The Wharton School between 2003 and 2005, and Philadelphia College of Pharmacy & Science.

Dr. Bergstein is Chief Executive Officer and Founder of Stemline Therapeutics. He led Stemline through multiple rounds of private financing and ultimately its successful IPO and subsequent follow-on offering, raising over $100 million as a public company. Prior to founding Stemline, Dr. Bergstein was Medical Director of Access Oncology, Inc., a clinical stage oncology-focused biotechnology company where he was a key member of a small team responsible for the acquisition and development of the company’s clinical stage assets and ultimately the sale of the company. Previously, he was a senior biopharmaceuticals analyst at a Wall Street-based firm that advised mutual funds and hedge funds on investments in public companies with late clinical stage assets. Dr. Bergstein received a B.A. in Mathematics from the University of Pennsylvania. He subsequently earned an M.D. from the Mount Sinai Medical Center where he was named to the Alpha Omega Alpha Medical Honor Society, was recipient of the Merck Award for Clinical Excellence, and subsequently completed a general surgery internship. He was then named the Jerome A. Urban post-doctoral fellow at Cornell University Medical College where he published work concerning oncogenes in breast cancer. Dr. Bergstein then completed a residency in internal medicine and a clinical fellowship in hematology-medical oncology at the New York Presbyterian Hospital-Weill Medical College of Cornell University, where he is currently a voluntary faculty member.

Chief Executive Officer and member of the board of XOMA (NASDAQ: XOMA). Joined XOMA in 2009 and was appointed to the CEO role in late 2016. In early 2017, Mr. Neal led XOMA through a dramatic strategic pivot taking the company from a traditional R&D heavy biotech company and transforming it to a successful royalty monetization and aggregation company. In the years prior to becoming CEO of XOMA, he was instrumental in leading the company’s licensing and business development activities focused on maximizing the value of XOMA’s foundational antibody IP and knowhow. In addition to his role at XOMA, Mr. Neal currently serves as a Director at Leading Biosciences, a clinical stage biotech company based in Carlsbad, CA. Mr. Neal has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Prior to XOMA, Mr. Neal was Acting Chief Executive Officer of Entelos Inc., a leading bio-simulation company that acquired Iconix Biosciences, a privately held company where Mr. Neal was Chief Executive Officer. At Iconix, Mr. Neal established multi-year collaborations with Bristol-Myers Squibb, Abbott Labs (now AbbVie), Eli Lilly and the U.S. Food and Drug Administration. From 1999-2002, he was Executive Vice President of Incyte Genomics, leading global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis, GSK and others. Earlier in his career, he was an executive with Monsanto Company in positions of increasing responsibility. Mr. Neal earned his B.S. in Biology and his M.S. in Genetics and Plant Breeding from the University of Manitoba, Canada, and holds an MBA degree from Washington University in St. Louis, MO.

Alexander Hardy is the CEO of Genentech. Hardy, who joined Genentech in 2005, has served as CEO since March 1, 2019. He previously served as head of global product Strategy for Roche Pharmaceuticals. Previously, he headed up Asia Pacific for Roche's pharma outfit.

Speck Loe works at Medimmune and a Ceo at Medimmune and is based in Granite Falls, Washington.

CR Ocean Engineering is a Samuel W. Croll, III, Chief Executive Officer of CR Ocean Engineering at Life Sciences - Search Solution Group.